Annual revenues for OxyContin continued to soar, and in the aftermath of the criminal case in Virginia, they reached a new high, of $3 billion. Having faced down a potentially mortal threat to its existence, OxyContin was booming. And it wasn’t just that Purdue kept selling the drug. The company continued to engage in the very same aggressive marketing tactics that it had vowed to put an end to.
